Agnos Therapeutics Overview

  • Year Founded
  • 2025

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 6

Agnos Therapeutics General Information

Description

Developer of a mutation-agnostic retinal cell therapy designed to restore vision for inherited blindness. The company utilizes induced pluripotent stem cell technology to create retinal cells that function independently of a patient's specific genetic mutation, providing a universal approach to treating various forms of inherited blindness through a proprietary regenerative process, enabling healthcare professionals to restore sight in patients with various genetic forms of retinal blindness.

Contact Information

Website
www.agnostx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1205 North Gay Street
  • Baltimore, MD 21213
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 1205 North Gay Street
  • Baltimore, MD 21213
  • United States

Agnos Therapeutics Timeline

2026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Agnos Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Accelerator/Incubator 29-Jan-2026 Completed Clinical Trials - General
4. Early Stage VC 01-Jan-2026 Completed Clinical Trials - General
3. Accelerator/Incubator 10-Jun-2025 Completed Clinical Trials - General
2. Accelerator/Incubator Completed Clinical Trials - General
1. University Spin-Out 01-Jan-2025 Completed Clinical Trials - General
To view Agnos Therapeutics’s complete valuation and funding history, request access »

Agnos Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Japan External Trade Organization Accelerator/Incubator
BioAdvance Capital (Conshohocken) Venture Capital Minority
Retinal Degeneration Fund Not-For-Profit Venture Capital Minority
Advanced Regenerative Manufacturing Institute Corporation
Johns Hopkins University University
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

Agnos Therapeutics FAQs

  • When was Agnos Therapeutics founded?

    Agnos Therapeutics was founded in 2025.

  • Where is Agnos Therapeutics headquartered?

    Agnos Therapeutics is headquartered in Baltimore, MD.

  • What industry is Agnos Therapeutics in?

    Agnos Therapeutics’s primary industry is Drug Discovery.

  • Is Agnos Therapeutics a private or public company?

    Agnos Therapeutics is a Private company.

  • What is Agnos Therapeutics’s current revenue?

    The current revenue for Agnos Therapeutics is .

  • How much funding has Agnos Therapeutics raised over time?

    Agnos Therapeutics has raised $2.5M.

  • Who are Agnos Therapeutics’s investors?

    Japan External Trade Organization, BioAdvance Capital (Conshohocken), Retinal Degeneration Fund, Advanced Regenerative Manufacturing Institute, and Johns Hopkins University are 5 of 6 investors who have invested in Agnos Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process